Haemonetics Corporation (HAE) Launches PerQseal Elite, Advancing Minimally Invasive Vascular Care
In 2025, the company launched the PerQseal Elite vascular closure system, receiving European CE Mark approval.
Haemonetics Corp (HAE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Royce & Associates Chuck Royce | 1,271,057 | $94,833,563 | +10% | 0.97% |
| 2. | SG Capital Management Ken Grossman And Glen Schneider | 906,892 | $67,663,212 | +27% | 4.68% |
| 3. | Fisher Asset Management Ken Fisher | 689,142 | $51,416,884 | -7% | 0.02% |
| 4. | 48,570,000 | $47,045,813 | 2.25% | ||
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 515,970 | $38,496,519 | -21% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.93 | 4,000 | $323,720.00 | 12,048 | 2020-08-11 | Filing | |
| $35.00 | 60,000 | $2,099,754.00 | 105,867 | 2016-08-04 | Filing | |
| $32.73 | 412 | $13,482.70 | 31,522 | 2013-04-30 | Filing | |
| $32.73 | 615 | $20,125.88 | 17,279 | 2013-04-30 | Filing | |
| $32.73 | 245 | $8,017.63 | 16,751 | 2013-04-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.15 | 4,312 | $393,038.80 | 18,196 | 2024-07-26 | Filing | |
| $90.00 | 79 | $7,110.00 | 21,331 | 2024-07-12 | Filing | |
| $90.00 | 2,136 | $192,240.00 | 21,410 | 2024-07-11 | Filing | |
| $88.57 | 4,094 | $362,605.58 | 31,257 | 2024-05-29 | Filing | |
| $87.86 | 8,896 | $781,602.56 | 35,351 | 2024-05-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,712 | $424,623 | 0.05% | |
| 2. | 124 | $6,044 | 0% |
News See All
13 Most Oversold Healthcare Stocks So Far in 2025
The healthcare innovation landscape in 2025 is navigating a complex mix of challenges and opportunities, marked by contrasting trends in fundraising, investment, and technology adoption.
Mizuho Reduces PT on Haemonetics Corporation (HAE) Following Fiscal Q1 2025 Results
On August 14, 2025, Mizuho reduced its price target on Haemonetics Corporation (NYSE:HAE) from $90 to $70, maintaining an ‘Outperform’ rating.
13 Oversold Value Stocks to Invest in Now
Amid Wall Street’s latest pullback, opportunities have emerged beyond the high-priced tech companies that have dominated the market in 2025.
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Haemonetics Corporation First Quarter 2026 Earnings Call. [Operator Instructions].
Haemonetics Builds Momentum with New Buy Rating and Growth Promise
Headquartered in Massachusetts, Haemonetics Corporation (NYSE:HAE) is engaged in the development and supply of innovative medical technologies and systems for blood and plasma collection, surgical cell...
11 Best Long Term Low Risk Stocks to Invest in
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment.
Haemonetics Corporation (NYSE:HAE) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call.
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts
Since President Trump announced new tariffs, the U.S. stock market has been steadily declining. The Wall Street Journal has estimated the loss to be around $6.6 trillion.
10 Pro-Life Companies to Invest In Now
Investing isn’t just about numbers—it’s also about values.
Hedge Fund Resource Center Billionaire Hedge Funds
